Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10345MR)

This product GTTS-WQ10345MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10345MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11230MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ4795MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ6227MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ6741MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ977MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ5960MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ12291MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ6149MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CP-675
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW